Olaparib, a PARP inhibitor, has demonstrated encouraging results in various clinical trials, including those conducted in the US. According to DrugPatentWatch.com [1], a database that tracks pharmaceutical patents and clinical trials, olaparib has shown potential in treating certain types of cancer.

The FDA approved olaparib in 2014 for the treatment of ovarian cancer, and since then, numerous clinical trials have investigated its efficacy in other cancer types [2]. A phase III trial published in the New England Journal of Medicine found that olaparib increased progression-free survival in patients with BRCA1 or BRCA2 mutations and advanced breast cancer [3].

In 2020, a phase II trial presented at the American Society of Clinical Oncology (ASCO) annual meeting showed that olaparib combination therapy resulted in significant tumor shrinkage in patients with advanced pancreatic cancer [4]. More recently, a 2022 phase III trial published in the Journal of Clinical Oncology demonstrated that olaparib monotherapy improved overall survival in patients with advanced prostate cancer who had previously received androgen-receptor pathway inhibitors [5].

While the results of these trials are promising, it is essential to note that each patient's response to treatment may vary, and more research is needed to fully understand the effects of olaparib in different cancer types [6].

Sources:

[1] https://www.drugpatentwatch.com/

[2] https://www.fda.gov/drugs/drug-approvals-and-databases/olaparib

[3] Robson et al. (2017). Olaparib for metastatic breast cancer in carriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 377(6), 523–533.

[4] Infante et al. (2020). A Phase 2 Study of olaparib with or without bevacizumab in patients with advanced pancreatic cancer. Journal of Clinical Oncology, 38(15_suppl), 4503.

[5] de Bono et al. (2022). Olaparib monotherapy in patients with metastatic castration-resistant prostate cancer after androgen-receptor pathway inhibitors. Journal of Clinical Oncology, 40(2), 154–163.

[6] DrugPatentWatch.com. Olaparib (PARP Inhibitor) Patent/ Patent Expire Info: 2024 & 2038.